{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:10:12Z","timestamp":1756483812611,"version":"3.44.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"DOI":"10.7759\/cureus.91238","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T15:32:43Z","timestamp":1756481563000},"source":"Crossref","is-referenced-by-count":0,"title":["Access to Naloxone and Preferences for Its Online Purchase Among Individuals Affected by Opioid Misuse"],"prefix":"10.7759","author":[{"given":"Rahul","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Drug overdose deaths. facts and figures. Accessed: June 26, 2025: https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates."},{"key":"ref2","unstructured":"Understanding the opioid overdose epidemic. Accessed. June 26, 2025: https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html."},{"key":"ref3","unstructured":"Physicians\u2019 Progress Toward Ending the Nation\u2019s Drug Overdose and Death Epidemic. (2020). Accessed. June 26, 2025: https:\/\/www.ama-assn.org\/system\/files\/2020-07\/opioid-task-force-progress-report.pdf."},{"key":"ref4","unstructured":"Early Changes in Waivered Clinicians and Utilization of Buprenorphine for Opioid Use Disorder After Implementation of the 2021 HHS Buprenorphine Practice Guidelines. (2022). Accessed. June 26, 2025: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/facbce1704035fded1034192d148304d\/buprenorphine-practice-guideline-...."},{"key":"ref5","unstructured":"Fentanyl. Accessed. June 26, 2025: https:\/\/www.cdc.gov\/overdose-prevention\/about\/fentanyl.html."},{"key":"ref6","unstructured":"Naloxone. Accessed. June 26, 2025: https:\/\/www.samhsa.gov\/medication-assisted-treatment\/medications-counseling-related-conditions\/naloxone."},{"key":"ref7","unstructured":"Naloxone overdose prevention laws. Accessed. June 26, 2025: http:\/\/pdaps.org\/datasets\/laws-regulating-administration-of-naloxone-1501695139.."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.0272","article-title":"Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose","volume":"179","author":"Abouk R","year":"2019","unstructured":"Abouk R, Pacula RL, Powell D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med. 2019, 179:805-11. 10.1001\/jamainternmed.2019.0272","journal-title":"JAMA Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6831e1","article-title":"Vital signs: pharmacy-based naloxone dispensing \u2014 United States, 2012-2018","volume":"68","author":"Guy GP Jr","year":"2019","unstructured":"Guy GP Jr, Haegerich TM, Evans ME, Losby JL, Young R, Jones CM. Vital signs: pharmacy-based naloxone dispensing \u2014 United States, 2012-2018. MMWR Morb Mortal Wkly Rep. 2019, 68:679-86. 10.15585\/mmwr.mm6831e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review","volume":"35","author":"Mackey K","year":"2020","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020, 35:954-63. 10.1007\/s11606-020-06257-4","journal-title":"J Gen Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12291","article-title":"Provision of naloxone without a prescription by California pharmacists 2 years after legislation implementation","volume":"320","author":"Puzantian T","year":"2018","unstructured":"Puzantian T, Gasper JJ. Provision of naloxone without a prescription by California pharmacists 2 years after legislation implementation. JAMA. 2018, 320:1933-4. 10.1001\/jama.2018.12291","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0022042620945673","article-title":"Optimizing the distribution of pharmacy-dispensed naloxone using spatial mapping techniques in rural areas","volume":"50","author":"Banerjee S","year":"2020","unstructured":"Banerjee S. Optimizing the distribution of pharmacy-dispensed naloxone using spatial mapping techniques in rural areas. J Drug Issue. 2020, 50:604-12. 10.1177\/0022042620945673","journal-title":"J Drug Issue"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108388","article-title":"Socio-ecological and pharmacy-level factors associated with naloxone stocking at standing-order naloxone pharmacies in New York City","volume":"218","author":"Abbas B","year":"2021","unstructured":"Abbas B, Marotta PL, Goddard-Eckrich D, Huang D, Schnaidt J, El-Bassel N, Gilbert L. Socio-ecological and pharmacy-level factors associated with naloxone stocking at standing-order naloxone pharmacies in New York City. Drug Alcohol Depend. 2021, 218:108388. 10.1016\/j.drugalcdep.2020.108388","journal-title":"Drug Alcohol Depend"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.07.008","article-title":"Factors associated with how often community pharmacists offer and dispense naloxone","volume":"15","author":"Carpenter DM","year":"2019","unstructured":"Carpenter DM, Dhamanaskar AK, Gallegos KL, Shepherd G, Mosley SL, Roberts CA. Factors associated with how often community pharmacists offer and dispense naloxone. Res Social Adm Pharm. 2019, 15:1415-8. 10.1016\/j.sapharm.2018.07.008","journal-title":"Res Social Adm Pharm"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.06.016","article-title":"Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review","volume":"60","author":"Thakur T","year":"2020","unstructured":"Thakur T, Frey M, Chewning B. Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review. J Am Pharm Assoc (2003). 2020, 60:178-94. 10.1016\/j.japh.2019.06.016","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000492","article-title":"Naloxone availability and pharmacy staff knowledge of standing order for naloxone in Pennsylvania pharmacies","volume":"13","author":"Graves RL","year":"2019","unstructured":"Graves RL, Andreyeva E, Perrone J, Shofer FS, Merchant RM, Meisel ZF. Naloxone availability and pharmacy staff knowledge of standing order for naloxone in Pennsylvania pharmacies. J Addict Med. 2019, 13:272-8. 10.1097\/ADM.0000000000000492","journal-title":"J Addict Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2018.04.025","article-title":"Identifying barriers to dispensing naloxone: a survey of community pharmacists in North Carolina","volume":"58","author":"Rudolph SE","year":"2018","unstructured":"Rudolph SE, Branham AR, Rhodes LA, Hayes HH Jr, Moose JS, Marciniak MW. Identifying barriers to dispensing naloxone: a survey of community pharmacists in North Carolina. J Am Pharm Assoc (2003). 2018, 58:S55-S58.e3. 10.1016\/j.japh.2018.04.025","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2017.1391924","article-title":"Barriers and facilitators to dispensing of intranasal naloxone by pharmacists","volume":"39","author":"Bakhireva LN","year":"2018","unstructured":"Bakhireva LN, Bautista A, Cano S, Shrestha S, Bachyrycz AM, Cruz TH. Barriers and facilitators to dispensing of intranasal naloxone by pharmacists. Subst Abus. 2018, 39:331-41. 10.1080\/08897077.2017.1391924","journal-title":"Subst Abus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-019-00349-1","article-title":"Beliefs associated with pharmacy-based naloxone: a qualitative study of pharmacy-based naloxone purchasers and people at risk for opioid overdose","volume":"96","author":"Donovan E","year":"2019","unstructured":"Donovan E, Case P, Bratberg JP, Baird J, Burstein D, Walley AY, Green TC. Beliefs associated with pharmacy-based naloxone: a qualitative study of pharmacy-based naloxone purchasers and people at risk for opioid overdose. J Urban Health. 2019, 96:367-78. 10.1007\/s11524-019-00349-1","journal-title":"J Urban Health"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.07.003","article-title":"Awareness and access to naloxone necessary but not sufficient: examining gaps in the naloxone cascade","volume":"59","author":"Tobin K","year":"2018","unstructured":"Tobin K, Clyde C, Davey-Rothwell M, Latkin C. Awareness and access to naloxone necessary but not sufficient: examining gaps in the naloxone cascade. Int J Drug Policy. 2018, 59:94-7. 10.1016\/j.drugpo.2018.07.003","journal-title":"Int J Drug Policy"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2020.1797811","article-title":"Access and barriers to take-home naloxone use among emergency department patients with opioid misuse in Baltimore, Maryland, USA","volume":"55","author":"Hurt BR","year":"2020","unstructured":"Hurt BR, Hussain A, Aledhaim A, Moayedi S, Schenkel SM, Kim HK. Access and barriers to take-home naloxone use among emergency department patients with opioid misuse in Baltimore, Maryland, USA. Subst Use Misuse. 2020, 55:2237-42. 10.1080\/10826084.2020.1797811","journal-title":"Subst Use Misuse"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.1915915","article-title":"Patient perspectives of barriers to naloxone obtainment and use in a primary care, underserved setting: A qualitative study","volume":"42","author":"Ko J","year":"2021","unstructured":"Ko J, Chan E, Doroudgar S. Patient perspectives of barriers to naloxone obtainment and use in a primary care, underserved setting: A qualitative study. Subst Abus. 2021, 42:1030-9. 10.1080\/08897077.2021.1915915","journal-title":"Subst Abus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.09.008","article-title":"Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA","volume":"74","author":"Bessen S","year":"2019","unstructured":"Bessen S, Metcalf SA, Saunders EC, et al.. Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA. Int J Drug Policy. 2019, 74:144-51. 10.1016\/j.drugpo.2019.09.008","journal-title":"Int J Drug Policy"},{"key":"ref24","unstructured":"Walgreens brand naloxone available online and in stores this month. Accessed. June 26, 2025: https:\/\/investor.walgreensbootsalliance.com\/news-releases\/news-release-details\/walgreens-brand-naloxone-available-onl...."},{"key":"ref25","unstructured":"Naloxone distribution project. Accessed. August 8, 2025: https:\/\/www.dhcs.ca.gov\/individuals\/Pages\/Naloxone_Distribution_Project.aspx."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01236-6","article-title":"Vending machines for reducing harm associated with substance use and use disorders, and co-occurring conditions: a systematic review","volume":"22","author":"Zhang A","year":"2025","unstructured":"Zhang A, Carrillo M, Liu R, Ballard SM, Reedy-Cooper A, Zgierska AE. Vending machines for reducing harm associated with substance use and use disorders, and co-occurring conditions: a systematic review. Harm Reduct J. 2025, 22:89. 10.1186\/s12954-025-01236-6","journal-title":"Harm Reduct J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.09.018","article-title":"Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates","volume":"94","author":"Becker WC","year":"2008","unstructured":"Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008, 94:38-47. 10.1016\/j.drugalcdep.2007.09.018","journal-title":"Drug Alcohol Depend"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.09.015","article-title":"'I have it just in case' - naloxone access and changes in opioid use behaviours","volume":"51","author":"Heavey SC","year":"2018","unstructured":"Heavey SC, Chang YP, Vest BM, Collins RL, Wieczorek W, Homish GG. 'I have it just in case' - naloxone access and changes in opioid use behaviours. Int J Drug Policy. 2018, 51:27-35. 10.1016\/j.drugpo.2017.09.015","journal-title":"Int J Drug Policy"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2196\/22411","article-title":"Reasons people who use opioids do not accept or carry no-cost naloxone: qualitative interview study","volume":"4","author":"Bennett AS","year":"2020","unstructured":"Bennett AS, Freeman R, Des Jarlais DC, Aronson ID. Reasons people who use opioids do not accept or carry no-cost naloxone: qualitative interview study. JMIR Form Res. 2020, 4:e22411. 10.2196\/22411","journal-title":"JMIR Form Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-69239-5","article-title":"Statistical Data Analysis Using SAS","author":"Marasinghe MG","year":"2018","unstructured":"Marasinghe MG, Koehler KJ. Statistical Data Analysis Using SAS. Springer, Cham; 2018. 10.1007\/978-3-319-69239-5"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00466-8","article-title":"Practical implications of naloxone knowledge among suburban people who use opioids","volume":"18","author":"Schneider KE","year":"2021","unstructured":"Schneider KE, Urquhart GJ, Rouhani S, Park JN, Morris M, Allen ST, Sherman SG. Practical implications of naloxone knowledge among suburban people who use opioids. Harm Reduct J. 2021, 18:47. 10.1186\/s12954-021-00466-8","journal-title":"Harm Reduct J"},{"key":"ref32","unstructured":"Naloxone Economic Review. Accessed. June 26, 2025: https:\/\/reaganudall.org\/sites\/default\/files\/2023-03\/Naloxone%20Report%20FINAL%203.8.23.pdf."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.07.012","article-title":"Evaluation of a pharmacist-led naloxone coprescribing program in primary care","volume":"59","author":"Cariveau D","year":"2019","unstructured":"Cariveau D, Fay AE, Baker D, Fagan EB, Wilson CG. Evaluation of a pharmacist-led naloxone coprescribing program in primary care. J Am Pharm Assoc (2003). 2019, 59:867-71. 10.1016\/j.japh.2019.07.012","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.09.007","article-title":"Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas","volume":"60","author":"Evoy KE","year":"2020","unstructured":"Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. J Am Pharm Assoc (2003). 2020, 60:81-6. 10.1016\/j.japh.2019.09.007","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/add.14634","article-title":"The impact of expanded Medicaid eligibility on access to naloxone","volume":"114","author":"Frank RG","year":"2019","unstructured":"Frank RG, Fry CE. The impact of expanded Medicaid eligibility on access to naloxone. Addiction. 2019, 114:1567-74. 10.1111\/add.14634","journal-title":"Addiction"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13125","article-title":"Will converting naloxone to over-the-counter status increase pharmacy sales?","volume":"54","author":"Murphy SM","year":"2019","unstructured":"Murphy SM, Morgan JR, Jeng PJ, Schackman BR. Will converting naloxone to over-the-counter status increase pharmacy sales?. Health Serv Res. 2019, 54:764-72. 10.1111\/1475-6773.13125","journal-title":"Health Serv Res"},{"key":"ref37","unstructured":"Naloxone is now available over-the-counter. Will it still be affordable?. Accessed. June 26, 2025: https:\/\/healthlaw.org\/naloxone-is-now-available-over-the-counter-will-it-still-be-affordable\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388278-access-to-naloxone-and-preferences-for-its-online-purchase-among-individuals-affected-by-opioid-misuse","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T15:32:44Z","timestamp":1756481564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388278-access-to-naloxone-and-preferences-for-its-online-purchase-among-individuals-affected-by-opioid-misuse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.91238","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}